Search Results - "ADINOLFI, L. E"

Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection by Coppola, N., Marrone, A., Pisaturo, M., Starace, M., Signoriello, G., Gentile, I., Adinolfi, L. E., Sagnelli, E., Zampino, R.

“…The purpose of this investigation was to evaluate the role of IL28-B polymorphism in the clearance of hepatitis C virus (HCV) in chronic hepatitis B virus…”
Get full text

Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C by Zampino, R., Coppola, N., Cirillo, G., Boemio, A., Pisaturo, M., Marrone, A., Macera, M., Sagnelli, E., Perrone, L., Adinolfi, L. E., Miraglia del Giudice, E.

“…Summary The patatin‐like phospholipase domain‐containing 3 gene (PNPLA3) and the apolipoprotein C3 gene (APOC3) have been studied in relation to liver…”
Get full text

Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor‐α in chronic hepatitis C patients by DURANTE‐MANGONI, E., ZAMPINO, R., MARRONE, A., TRIPODI, M.‐F., RINALDI, L., RESTIVO, L., CIOFFI, M., RUGGIERO, G., ADINOLFI, L. E.

“…Summary Background Steatosis and insulin resistance (IR) have a pathogenic role in chronic hepatitis C (HCV). Adipocytokines balance modulates hepatic lipid…”
Get full text

Streptococcus bovis Endocarditis and Its Association with Chronic Liver Disease: An Underestimated Risk Factor by Tripodi, M. F., Adinolfi, L. E., Ragone, E., Mangoni, E. Durante, Fortunato, R., Iarussi, D., Ruggiero, G., Utili, R.

“…Clinical and epidemiological characteristics of Streptococcus bovis endocarditis were prospectively studied among 199 patients with definite endocarditis…”
Get full text

Hepatitis C and steatosis: a reappraisal by Lonardo, A., Loria, P., Adinolfi, L. E., Carulli, N., Ruggiero, G.

“…The overall prevalence of steatosis in patients with Hepatitis C virus (HCV) chronic infection is 55.5% (range 34.8–81.2%). This is a two to threefold increase…”
Get full text

Review article: hepatitis C virus‐associated steatosis – pathogenic mechanisms and clinical implications by ADINOLFI, L. E., DURANTE‐MANGONI, E., ZAMPINO, R., RUGGIERO, G.

“…Summary Steatosis is a common feature of chronic hepatitis C, and may be caused directly by the virus, as in genotype 3 infection, or be associated with host…”
Get full text

Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial by Adinolfi, L E, Utili, R, Tonziello, A, Ruggiero, G

“…Background: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for…”
Get full text

Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C by ADINOLFI, Luigi E, UTILI, Riccardo, ANDREANA, Augusto, TRIPODI, Marie-Francoise, MARRACINO, Marta, GAMBARDELLA, Michele, GIORDANO, Mariagrazia, RUGGIERO, Giuseppe

“…The role of HCV RNA levels and host factors in the severity of liver injury was studied. Enrolled were 298 consecutive liver biopsy-proven chronic hepatitis…”
Get full text

Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients by Zampino, R., Ingrosso, D., Durante-Mangoni, E., Capasso, R., Tripodi, M.-F., Restivo, L., Zappia, V., Ruggiero, G., Adinolfi, L. E.

“…(A) A reduced activity of microsomal triglyceride transfer protein (MTP), a key enzyme of assembly/secretion of lipoproteins, is related to HCV steatosis. Host…”
Get full text

Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee by Loria, P, Adinolfi, L E, Bellentani, S, Bugianesi, E, Grieco, A, Fargion, S, Gasbarrini, A, Loguercio, C, Lonardo, A, Marchesini, G, Marra, F, Persico, M, Prati, D, Baroni, G Svegliati

“…We report the evidence-based Italian Association for the Study of Liver guidelines for the appropriate diagnosis and management of patients with nonalcoholic…”
Get full text

Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study by Sasso, F.C., Pafundi, P.C., Gelso, A., Bono, V., Costagliola, C., Marfella, R., Sardu, C., Rinaldi, L., Galiero, R., Acierno, C., Caturano, A., de Sio, C., De Nicola, L., Salvatore, T., Nevola, R., Adinolfi, L.E., Minutolo, R., Giugliano, D., Maiorino, M.I., Riccardi, G., Bozzetto, L., Guardasole, V., Di Palo, R., Carbonara, O., Riccio, M., De Simone, G., Lucibelli, L., Masi, S.

“…Recently, the albuminocentric view of diabetic kidney disease (DKD) in type 2 diabetes (T2DM) has been changing. Therefore, the relationship between diabetic…”
Get full text

Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti‐hepatitis B e‐positive chronic hepatitis by MARRONE, A., ZAMPINO, R., KARAYANNIS, P., CIRILLO, G., CESARO, G., GUERRERA, B., RICCIOTTI, R., MIRAGLIA DEL GIUDICE, E., UTILI, R., ADINOLFI, L. E., RUGGIERO, G.

“…Summary Background : Drug‐resistant mutants may emerge in patients with chronic hepatitis B receiving lamivudine therapy. Aim : To evaluate whether different…”
Get full text

Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy by Marrone, A., Capoluongo, N., D'Amore, C., Pisaturo, M., Esposito, M., Guastafierro, S., Siniscalchi, I., Macera, M., Boemio, A., Onorato, L., Rinaldi, L., Minichini, C., Adinolfi, L. E., Sagnelli, E., Mastrullo, L., Coppola, N.

“…Summary This study evaluated the long‐term efficacy and safety of an 18‐month lamivudine prophylaxis in 68 HBsAg‐negative/anti–HBc‐positive patients with…”
Get full text

Editorial - Role of Highly Active Antiretroviral Therapy (HAART) for the COVID-19 treatment by Nastri, B M, Zannella, C, Folliero, V, Rinaldi, L, Restivo, L, Stelitano, D, Sperlongano, R, Adinolfi, L E, Franci, G

Get more information

Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemic by Nevola, R, Marrone, A, Cozzolino, D, Cuomo, G, Romano, C P, Rinaldi, L, Aprea, C, Padula, A, Ranieri, R, Gjeloshi, K, Ricozzi, C, Ruosi, C, Imbriani, S, Meo, L A, Sellitto, A, Cinone, F, Carusone, C, Abitabile, M, Nappo, F, Signoriello, G, Adinolfi, L E

“…The first pandemic phase of COVID-19 in Italy was characterized by high in-hospital mortality ranging from 23% to 38%. During the third pandemic phase there…”
Get more information

Editorial - HCC in HCV patients and the direct acting antivirals: is there really a link? by Marrone, A, Franci, G, Perrella, A, Nevola, R, Chianese, A, Adinolfi, L E, Sasso, F C, Rinaldi, L

Get more information

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR by Restivo, L., Zampino, R., Guerrera, B., Ruggiero, L., Adinolfi, L. E.

“…HCV genotypes 2‐ or 3‐infected patients with a rapid virological response (RVR) to therapy with pegylated interferon and ribavirins who have a low viral load,…”
Get full text

The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B by Coppola, N., Zampino, R., Bellini, G., Stanzione, M., Capoluongo, N., Marrone, A., Macera, M., Pasquale, G., Boemio, A., Maione, S., Adinolfi, L.E., Del Giudice, E. Miraglia, Sagnelli, E., Rossi, F.

“…The impact of the cannabinoid receptor 2 (CB2) rs35761398 polymorphism on chronic hepatitis B (CHB) was evaluated in 106 consecutive biopsy-proven CHB patients…”
Get full text

Effect of hepatitis B virus on steatosis in hepatitis C virus co‐infected subjects: A multi‐centre study and systematic review by Goossens, N., Vito, C., Mangia, A., Clément, S., Cenderello, G., Barrera, F., D'Ambrosio, R., Coppola, N., Zampino, R., Stanzione, M., Adinolfi, L. E., Wedemeyer, H., Semmo, N., Müllhaupt, B., Semela, D., Malinverni, R., Moradpour, D., Heim, M., Trincucci, G., Rubbia‐Brandt, L., Negro, F., Piazzolla, Valeria, Santoro, Rosanna, Dufour, Jean‐Francois, Brunner, Barbara, Weber, Achim, Herranz, Maribelle, Mathieu, Adeline, Clerc, Olivier, Elisabetta, Degasperi, Floriana, Facchetti, Macera, Margherita, Pisaturo, Mariantonietta, Stornaiuolo, Gianfranca, Rinaldi, Luca, George, Jacob, Mix, Carola, Cornberg, Markus

“…Summary It remains unclear whether hepatitis B virus (HBV) infection may modify the severity of viral steatosis in patients coinfected with chronic hepatitis C…”
Get full text

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity by Adinolfi, Luigi E., Gambardella, Michele, Andreana, Augusto, Tripodi, Marie-françoise, Utili, Riccardo, Ruggiero, Giuseppe

“…The role of steatosis in the progression of liver damage in chronic hepatitis C (CHC) was studied. Enrolled were 180 consecutive liver biopsy-proven CHC…”
Get full text